MX2017015961A - Moduladores alostericos positivos del receptor m1 muscarinico. - Google Patents

Moduladores alostericos positivos del receptor m1 muscarinico.

Info

Publication number
MX2017015961A
MX2017015961A MX2017015961A MX2017015961A MX2017015961A MX 2017015961 A MX2017015961 A MX 2017015961A MX 2017015961 A MX2017015961 A MX 2017015961A MX 2017015961 A MX2017015961 A MX 2017015961A MX 2017015961 A MX2017015961 A MX 2017015961A
Authority
MX
Mexico
Prior art keywords
muscarinic
positive allosteric
allosteric modulators
receptor positive
compounds
Prior art date
Application number
MX2017015961A
Other languages
English (en)
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Anil Karbhari Shinde
Reddy Gagginapally Shankar
Rasheed Mohameed Abdul
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2017015961A publication Critical patent/MX2017015961A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invención está relacionada a un compuesto de la Fórmula (I), o estereoisómeros y sales farmacéuticamente aceptables como moduladores alostóricos positivos del receptor M1 muscarí­nico; esta invención también está relacionada a métodos para preparar tales compuestos y composiciones farmacóuticas que comprenden tales compuestos; los compuestos de esta invención son útiles en el tratamiento de varios trastornos que están relacionados al receptor M1 muscarí­nico. (ver Fórmula).
MX2017015961A 2015-06-08 2016-06-08 Moduladores alostericos positivos del receptor m1 muscarinico. MX2017015961A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2851CH2015 2015-06-08
PCT/IB2016/000771 WO2016198937A1 (en) 2015-06-08 2016-06-08 Muscarinic m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
MX2017015961A true MX2017015961A (es) 2018-07-06

Family

ID=56411822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015961A MX2017015961A (es) 2015-06-08 2016-06-08 Moduladores alostericos positivos del receptor m1 muscarinico.

Country Status (29)

Country Link
US (1) US10308620B2 (es)
EP (1) EP3303331B1 (es)
JP (1) JP6466602B2 (es)
KR (1) KR102052058B1 (es)
CN (1) CN107922400B (es)
AU (1) AU2016276139B2 (es)
BR (1) BR112017026272B1 (es)
CA (1) CA2987843C (es)
CY (1) CY1121693T1 (es)
DK (1) DK3303331T3 (es)
EA (1) EA032602B1 (es)
ES (1) ES2719626T3 (es)
HK (1) HK1247919A1 (es)
HR (1) HRP20190624T1 (es)
HU (1) HUE044902T2 (es)
IL (1) IL255994B (es)
LT (1) LT3303331T (es)
MA (1) MA43913B1 (es)
MD (1) MD3303331T2 (es)
ME (1) ME03379B (es)
MX (1) MX2017015961A (es)
NZ (1) NZ737892A (es)
PL (1) PL3303331T3 (es)
PT (1) PT3303331T (es)
RS (1) RS58665B1 (es)
SI (1) SI3303331T1 (es)
TR (1) TR201904639T4 (es)
WO (1) WO2016198937A1 (es)
ZA (1) ZA201708108B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234979B2 (en) * 2017-10-18 2022-02-01 Suven Life Sciences Limited Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators
CA3078164C (en) * 2017-10-27 2022-11-15 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
US20220152005A1 (en) * 2019-04-04 2022-05-19 Andrew Coop Methods of using muscarinic antagonists in the treatment of depression
KR102285472B1 (ko) 2019-06-14 2021-08-03 엘지전자 주식회사 음향의 이퀄라이징 방법과, 이를 구현하는 로봇 및 ai 서버
CN110606827B (zh) * 2019-09-26 2023-03-14 西安凯立新材料股份有限公司 一步法合成甲氨基吡啶类化合物的方法
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
JP5192389B2 (ja) 2005-12-05 2013-05-08 メルク・シャープ・エンド・ドーム・コーポレイション キノロンｍ１レセプター陽性アロステリックモジュレータ
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
JP2014076948A (ja) 2011-02-09 2014-05-01 Astellas Pharma Inc イソキノリンアミド誘導体
US9403802B2 (en) * 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9708278B2 (en) * 2013-11-27 2017-07-18 Vanderbilt University Substituted 4-benzyl-3,4-dihydro-2H-benzo[B][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor M1
GB201409044D0 (en) * 2014-05-21 2014-07-02 Ucl Business Plc New compounds

Also Published As

Publication number Publication date
JP2018521024A (ja) 2018-08-02
EP3303331A1 (en) 2018-04-11
CY1121693T1 (el) 2020-07-31
CN107922400A (zh) 2018-04-17
RS58665B1 (sr) 2019-06-28
MD3303331T2 (ro) 2019-05-31
TR201904639T4 (tr) 2019-05-21
US10308620B2 (en) 2019-06-04
EP3303331B1 (en) 2019-02-27
DK3303331T3 (en) 2019-04-23
CA2987843A1 (en) 2016-12-15
JP6466602B2 (ja) 2019-02-06
HUE044902T2 (hu) 2019-11-28
ZA201708108B (en) 2018-11-28
PT3303331T (pt) 2019-04-30
CN107922400B (zh) 2021-05-11
US20180155302A1 (en) 2018-06-07
PL3303331T3 (pl) 2019-06-28
CA2987843C (en) 2020-07-14
WO2016198937A1 (en) 2016-12-15
MA43913B1 (fr) 2019-05-31
NZ737892A (en) 2018-09-28
EA201792594A1 (ru) 2018-06-29
BR112017026272A2 (pt) 2018-09-11
EA032602B1 (ru) 2019-06-28
HRP20190624T1 (hr) 2019-05-31
ME03379B (me) 2020-01-20
KR102052058B1 (ko) 2019-12-04
IL255994A (en) 2018-01-31
AU2016276139B2 (en) 2018-07-19
KR20180016528A (ko) 2018-02-14
HK1247919A1 (zh) 2018-10-05
BR112017026272B1 (pt) 2023-04-11
IL255994B (en) 2018-04-30
ES2719626T3 (es) 2019-07-11
AU2016276139A1 (en) 2018-01-04
SI3303331T1 (sl) 2019-05-31
LT3303331T (lt) 2019-04-25
MA43913A (fr) 2018-04-11

Similar Documents

Publication Publication Date Title
SA518391624B1 (ar) Ror- منظمات جاما
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12018500259A1 (en) Muscarinic agonists
PH12016501791A1 (en) Muscarinic receptor agonists
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
WO2015001541A3 (en) Pharmaceutical film composition
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
PH12017501736A1 (en) Indole derivatives
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
FG Grant or registration